Back HCV Treatment

EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cures 100% Cure of Previously Untreated HCV Genotype 4

A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, as well as all treatment-experienced patients followed for 4 weeks post-treatment, Christophe Hézode of Hôpital Henri Mondor in Paris reported at the 49th EASL International Liver Congress last week in London.

alt

Read more: